Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidilmax offering a 0.5% Pyrilutamide solution and debating the cost, effectiveness, and safety of using it alone or with other treatments such as Finasteride and Minoxidil.

A user shared a new hair loss treatment protocol including topical dutasteride, latanoprost, caffeine, minoxidil, tretinoin, and triamcinolone acetonide. Others discussed the effectiveness and availability of these treatments, with some suggesting simpler oral alternatives.

The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

The user was prescribed 0.3% topical finasteride with 5% minoxidil for use on the temples twice daily, while continuing minoxidil on the full scalp. Replies suggested using the treatment once daily and questioned the logic of treating only the temples, with one suggesting dilution for use across the entire scalp.

The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Discouragement regarding Pyrilutamide, a drug in development for hair loss, and the potential side effects of Finasteride. People discussed anecdotal experiences with Pyrilutamide as well as suggestions to wait out Phase 3 trials before making any conclusions.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

RU58841 and pyrilutamide are being discussed as potential hair loss treatments, with some users reporting side effects. There is interest in these treatments as alternatives to 5ar inhibitors and oral minoxidil due to concerns about safety and side effects.

The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.

A user stopped finasteride after 15 years due to severe side effects, which improved after quitting. They maintained most of their hair and are considering alternatives like topical treatments or RU58841.

A user plans to order Pyrilutamide for hair loss after losing ground on finasteride. Another user advises against buying from Hairliciously, suggesting Amazon instead.

The conversation is about incorporating tretinoin into a topical minoxidil routine for better hair loss treatment. The user is considering compounded minoxidil sprays with tretinoin from brands like Keeps and Roman.

The conversation discusses alternatives to Dr. B's hair loss treatments, specifically mentioning Minoxidil, Finasteride, and RU58841. A user notes a price discrepancy on a website.

User discusses Alfatradiol (17a-Estradiol) as a potential hair loss treatment with mixed results. Concerns include low dosage, receptor theory, and possible increased aromatase activity on scalp.

Switching from finasteride to dutasteride and oral minoxidil worsened hair thinning at the hairline and temples. The user is considering returning to finasteride, as dutasteride may not be effective for them.

The user experienced initial success with topical finasteride 0.025% and melatonin but noticed rapid hair thinning after three months. They are considering switching to a higher dose of topical finasteride or oral finasteride, as advised by others, while being cautious about potential side effects.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

A user with diffuse thinning recommends a root cover-up spray as a temporary, medication-free solution. They plan to consult a dermatologist for treatments like Minoxidil and finasteride while using the spray for special occasions.

A user is using a Finoxidil topical spray and is curious if oral Finasteride would be more effective, considering they are already on a DHT blocker called Cyproterone. They are concerned about the potential impact of oral Finasteride on their transition.

The conversation discusses switching from finasteride to dutasteride due to side effects, with some users experiencing fewer side effects on dutasteride. It also mentions using liposomal topical finasteride and ketoconazole shampoo as alternative treatments.

Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.

OP used minoxidil for 15 months and pyrilutamide for 46 days, achieving desired results without side effects. Users discussed alternatives like dutasteride and finasteride, with concerns about side effects like erectile dysfunction.

Actifollic selling Pyrilutamide as a treatment for hair loss, with people debating its efficacy compared to Minoxidil and Finasteride in combination with RU58841.

The conversation discusses the effectiveness of pyrithione zinc and GT20029 for hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

This conversation discussed the potential for a hair loss treatment alternative to minoxidil, with many users debating the economic and health implications of such an option. Some suggested that finasteride could be used as an alternative, while others argued that this would ultimately not benefit pharmaceutical companies due to their reliance on planned obsolescence.

Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.

There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.